leisure time -WSS

leisure time

author：Wikipedia 2025-09-27 10:04:16 - browse：629

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： The surgeon had a dilemma only a Nazi medical text could resolve

WSS

Leading voice in opioid treatment defends methadone clinic system

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Orchard's therapy for neuron disease in children wins FDA approval

Copay coupons to count toward deductibles, after Biden court move

Asbestos, a deadly carcinogen, banned by EPA

Future doctors should be trained to promote social change

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Research misconduct: Proposed new rules face resistance

Malaria cases in Florida and Texas: Here’s what you need to know

Think you might have Covid

Hepatitis C has a cure — but many Americans still lack access to it

New brain studies show LSD's effects on the brain in full color

Tori Bowie and the unacceptable rates of Black maternal death

Francis Collins on trust in science and how Covid communications failed

Heart attack and stroke risk calculators need revising

Think you might have Covid

Wikipedia

AI generated plenty of interest at JPM but not a lot of trust

FDA clears AI tool for detecting skin cancer

Baby aspirin cuts fat buildup in liver disease patients, in small study

Dewpoint Therapeutics lays off staff after losing partnerships

Intermittent fasting comes with a heart risk? Not so fast

Independent physicians launch a new lobbying group

explore

explore

focus

focus